Relapse of imported vivax malaria despite standard-dose primaquine therapy: An investigation with molecular genotyping analyses

T. Y. Chiang, W. C. Lin, M. C. Kuo, D. D. Ji, C. T. Fang

Research output: Contribution to journalArticlepeer-review

8 Citations (Scopus)

Abstract

Taiwan CDC investigated four cases of recurrent imported vivax malaria during 2003-2010. Molecular genotyping results and the lack of inter-episodes travel history indicated that two of the patients, who acquired vivax malaria in Indonesia and the Solomon Islands, respectively, suffered relapses after an interval of 3-4months, despite completing standard-dose primaquine therapy (30mg/day for 14days) for the first episode. Treatment with a higher dose of primaquine (60mg/day for 14days) prevented further relapse in both patients. This finding calls for further monitoring of the therapeutic efficacy of primaquine in treating Plasmodium vivax acquired in southeast Asia and Oceania.

Original languageEnglish
Pages (from-to)E232-E234
JournalClinical Microbiology and Infection
Volume18
Issue number7
DOIs
Publication statusPublished - 2012 Jul

All Science Journal Classification (ASJC) codes

  • Microbiology (medical)
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Relapse of imported vivax malaria despite standard-dose primaquine therapy: An investigation with molecular genotyping analyses'. Together they form a unique fingerprint.

Cite this